Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan

Journal of Clinical Pharmacy and Therapeutics

Volumn 38, Issue 6, 2013, Pages 468-475

  Shimazawa, Rumiko ^a   Ikeda, M ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

biomarker; package inserts; personalized medicine; pharmacogenomics; polymorphism

Indexed keywords

ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; CYTOCHROME P450 2D6; ENZYME;

ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG INFORMATION; DRUG LABELING; DRUG PACKAGING; DRUG SAFETY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; JAPAN; MULTICENTER STUDY; PHARMACOGENOMICS; UNITED KINGDOM; UNITED STATES;

BIOMARKER; PACKAGE INSERTS; PERSONALIZED MEDICINE; PHARMACOGENOMICS; POLYMORPHISM;

BIOLOGICAL MARKERS; DRUG LABELING; DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYMES; GREAT BRITAIN; HUMANS; INFORMATION DISSEMINATION; JAPAN; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POPULATION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84886953287     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12089     Document Type: Article

References (50)

1. U.S. Food and Drug Administration. Guidance for Industry: Pharmacogenomic Data Submissions. March 2005. Available at: http://www.fda.gov/downloads/ Regula-toryInformation/Guidances/ucm126957.pdf (accessed 4 March 2013).
2. U.S. Food and Drug Administration. Genomics. Available at: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/default. htm (accessed 4 March 2013).
3. U.S. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labels. Available at: http://www.fda.gov/Drugs/ScienceResearch/ ResearchAreas/Pharmacogenetics/ucm083378.htm (accessed 4 March 2013).
4. European Medicines Agency. Multidisciplinary: Pharmacogenomics. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/ general-content-000411.jsp&mid=WC0b01ac058002958e&jsen-abled=true (accessed 4 March 2013).
5. Frueh FW, Amur S, Mummaneni P, et al,. Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy, 2008; 28: 992-998.
6. Zineh I, Gerhard T, Aquilante CL, Beitelshees AL, Beasley BN, Hartzema AG,. Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. Pharmacogenomics J, 2004; 4: 354-358.
7. Zineh I, Pebanco GD, Aquilante CL, Gerhard T, Beitelshees AL,. Discordance between availability of pharmacogenetics studies and pharmacogenetics-based prescribing information for the top 200 drugs. Ann Pharmacother, 2006; 40: 639-644.
8. Ishiguro A, Toyoshima S, Uyama Y,. Current Japanese regulatory situations of pharmacogenomics in drug administration. Expert Rev Clin Pharmacol, 2008; 1: 505-514.
9. Otsubo Y, Asahina Y, Noguchi A, Sato Y, Ando Y, Uyama Y,. Similarities and differences between US and Japan as to pharmacogenomic biomarker information in drug labels. Drug Metab Pharmacokinet, 2012; 27: 142-149.
10. Papaluca Amati M,. Personalised Medicine Towards the Market and Patients: The Approval Process. May 2011. Available at: http://ec.europa.eu/research/ health/pdf/event06/13052011/marisa-papaluca-amati-en.pdf (accessed 4 March 2013).
11. Weaver L, Donohue E, Hedtke B, et al,. Comparing health care systems. Can the United States learn from other countries? Minn Med, 2010; 93: 6-7.
12. U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ (accessed 4 March 2013).
13. National Library of Medicine. Daily Med. Available at: http://dailymed.nlm.nih.gov/dailymed/about.cfm (accessed 4 March 2013).
14. Datapharm Communications Limited. eMC. Available at: http://www. medicines.org.uk/emc/ (accessed 4 March 2013).
15. Pharmaceutical Medical Device Agency. Information of Ethical Drug Package Inserts. Available at: http://www.info.pmda.go.jp/psearch/html/menu-tenpu-base. html (accessed 4 March 2013).
16. U. S. Department of Health and Human Services. Requirements on content and format of labeling for human prescription drug and biological products. Fed Reg, 2006; 71: 3922-3997. Available at: http://edocket.access.gpo.gov/2006/pdf/ 06-545.pdf (accessed 4 March 2013).
17. European Commission. A Guideline on Summary of Product Characteristics. September 2009. Available at: http://ec.europa.eu/health/files/eudralex/vol-2/c/ smpc-guide-line-rev2-en.pdf (accessed 4 March 2013).
18. Pharmaceutical Affairs Bureau, Ministry of Health & Welfare. Notification No. 606 (in Japanese). Dated 25 April 1997.
19. U.S. Food and Drug Administration. Guidance for Industry: Labeling for Human Prescription Drug and Biological Products-Implementing the PLR Content and Format Requirements. February 2013. Available at: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM075082.pdf (accessed 4 March 2013).
20. Fukuhara H,. Period between world first launch and country launch (Japanese). OPIR Research Paper, 2006; No.31.
21. Tsuji K, Tsutani K,. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations. J Clin Pharm Ther, 2010; 35: 289-301.
22. Ridker PM, Miletich JP, Hennekens CH, Buring JE,. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA, 1997; 277: 1305-1307.
23. Shimizu T, Ochiai H, Asell F, et al,. Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet, 2003; 18: 48-70.
24. Poolsup N, Li Wan Po A, Knight TL,. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther, 2000; 25: 197-220.
25. European Medicines Agency. Guideline on the Use of Pharmacogenetic Methodologies in the Pharmacokinetic Evaluation of Medicinal Products. December 2011. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2012/02/WC500121954.pdf (accessed 4 March 2013).
26. U.S. Food and Drug Administration. Guidance for Industry: Clinical Pharmacology Section of Labeling for Human Prescription Drug and Biological Products-Content and Format. Draft guidance, February 2009. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM109739.pdf (accessed 4 March 2013).
27. U.S. Food and Drug Administration. Guidance for Industry: Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products-Content and Format. March 2010. Available at: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UC-M075066. pdf (accessed 4 March 2013).
28. U.S. Food and Drug Administration. FDA Drug Safety Communication: Reduced Effectiveness of Plavix (clopidogrel) in Patients Who are Poor Metabolizers of the Drug. March 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInform-ationforPatientsandProviders/ucm203888.htm (accessed 4 March 2013).
29. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM,. ACCF/AHA clopidogrel clinical alert: approaches to the FDA 'boxed warning': a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol, 2010; 56: 321-341.
30. Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D,. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ, 2011; 343: d4588.
31. Goetz MP, Knox SK, Suman VJ, et al,. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat, 2007; 101: 113-121.
32. Bonanni B, Macis D, Maisonneuve P, et al,. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol, 2006; 24: 3708-3709.
33. Nowell SA, Ahn J, Rae JM, et al,. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat, 2005; 91: 249-258.
34. Wegman P, Elingarami S, Carstensen J, Stål O, Nordenskjöld B, Wingren S,. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res, 2007; 9: R7.
35. Wegman P, Vainikka L, Stål O, et al,. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res, 2005; 7: R284-R290.
36. Schroth W, Antoniadou L, Fritz P, et al,. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol, 2007; 25: 5187-5193.
37. Kiyotani K, Mushiroda T, Sasa M, et al,. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci, 2008; 99: 995-999.
38. Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J,. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol, 2007; 25: 3837-3845.
39. Desta Z, Flockhart DA,. Germline pharmacogenetics of tamoxifen response: have we learned enough? J Clin Oncol, 2007; 25: 5147-5149.
40. Hayes DF, Stearns V, Rae J, Flockhart D, Consortium on Breast Cancer Pharmacogenomics. A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? J Natl Cancer Inst, 2008; 100: 610-613.
41. Flockhart DA, Skaar T, Berlin DS, Klein TE, Nguyen AT,. Clinically available pharmacogenomics tests. Clin Pharmacol Ther, 2009; 86: 109-113.
42. Schwarz UI, Stein CM,. Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants. Clin Pharmacol Ther, 2006; 80: 7-12.
43. Schwarz UI, Ritchie MD, Bradford Y, et al,. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med, 2008; 358: 999-1008.
44. Johnson JA, Gong L, Whirl-Carrillo M, et al,. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther, 2011; 90: 625-629.
45. Limdi NA, Veenstra DL,. Warfarin pharmacogenetics. Pharmacotherapy, 2008; 28: 1084-1097.
46. Tan GM, Wu E, Lam YY, Yan BP,. Role of warfarin pharmacogenetic testing in clinical practice. Pharmacotherapy, 2010; 11: 439-448.
47. Anderson JL, Horne BD, Stevens SM, et al,. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation, 2012; 125: 1997-2005.
48. Avery PJ, Jorgensen A, Hamberg AK, Wadelius M, Pirmohamed M, Kamali F, EU-PACT Study Group. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clin Pharmacol Ther, 2011; 90: 701-706.
49. Klein TE, Altman RB, Eriksson N, et al,. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med, 2009; 360: 753-764.
50. Meckley LM, Neumann PJ,. Personalized medicine: factors influencing reimbursement. Health Policy, 2010; 94: 91-100.